新华财经南京9月15日电(记者朱程)日前,国家药监局官网显示,中国生物制药旗下核心企业正大天晴药业集团自主研发的注射用醋酸地加瑞克(商标名:晴立舒)获批上市,用于需接受雄激素去势治疗的前列腺癌患者。据悉,正大天晴醋酸地加瑞克此前已在欧盟市场获批,成为全球首仿药,并在美国获得暂时批准。此次在国内申报审评过程中,正大天晴还同步发起专利挑战,成功宣告原研药2项核心权利要求无效,该产品也成为我国药品专利...
Source Link新华财经南京9月15日电(记者朱程)日前,国家药监局官网显示,中国生物制药旗下核心企业正大天晴药业集团自主研发的注射用醋酸地加瑞克(商标名:晴立舒)获批上市,用于需接受雄激素去势治疗的前列腺癌患者。据悉,正大天晴醋酸地加瑞克此前已在欧盟市场获批,成为全球首仿药,并在美国获得暂时批准。此次在国内申报审评过程中,正大天晴还同步发起专利挑战,成功宣告原研药2项核心权利要求无效,该产品也成为我国药品专利...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.